Atherosclerosis Drugs Rise With The Surge In Cardiovascular Diseases Is Supporting Development Across The Atherosclerosis Drugs Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Atherosclerosis Drugs Market Change Between 2026 And 2030?

The atherosclerosis drugs market size has shown consistent expansion in recent years. This market is projected to expand from $50.91 billion in 2025 to $52.45 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.0%. Historically, this growth has been influenced by factors such as the increasing occurrence of cardiovascular diseases, greater public awareness of heart health, the widespread adoption of statins and cholesterol-lowering drugs, government-led initiatives for cardiovascular care, and improvements in hospital and retail pharmacy infrastructure.

The atherosclerosis drugs market size is set to experience steady expansion in the coming years, with projections indicating it will reach $61.19 billion in 2030, at a compound annual growth rate (CAGR) of 3.9%. This growth throughout the forecast period is attributed to the increasing adoption of precision medicine in cardiovascular treatment, greater utilization of digital health monitoring tools, a rising need for combination therapies, the expanding geriatric population, and breakthroughs in novel anti-atherosclerosis drug classes. Significant trends anticipated during this period include personalized atherosclerosis therapy, combined drug formulations, support for minimally invasive treatments, proactive cardiovascular healthcare initiatives, and enhanced patient adherence alongside digital monitoring.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Significant Factors Are Encouraging Growth In The Atherosclerosis Drugs Market?

The anticipated increase in cardiovascular disease cases is set to boost the expansion of the atherosclerosis drug market. Cardiovascular diseases encompass a range of conditions impacting the heart and blood vessels, while atherosclerosis involves the accumulation of fats, cholesterol, and other matter on artery walls. This buildup of plaque within arteries is what leads to cardiovascular conditions such as coronary heart disease and stroke. Atherosclerosis drugs function by treating cardiovascular diseases, mitigating complication risks, and addressing underlying issues like elevated cholesterol and blood clots. For example, the American Heart Association, a US-based non-profit organization, reported in January 2024 that the age-adjusted death rate due to cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the widespread occurrence of cardiovascular diseases will propel the atherosclerosis drug market.

How Is The Atherosclerosis Drugs Market Structured Across Different Market Segments?

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor

2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements

3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril

4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics

5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants

6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol

7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil

8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

What Trends Are Impacting The Atherosclerosis Drugs Market?

Leading companies active in the atherosclerosis drugs market are developing novel products, such as anti-inflammatory medications, to boost their market profitability. Atherosclerosis anti-inflammatory drugs are treatments designed to reduce inflammation associated with atherosclerosis, a condition defined by plaque accumulation in arteries. For example, AGEPHA Pharma, a Europe-based producer of medical products, introduced LODOCO in June 2023. LODOCO (colchicine, 0.5 mg tablet) has received approval from the U.S. FDA as the inaugural anti-inflammatory atheroprotective cardiovascular treatment. The drug has demonstrated effectiveness in lowering the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. LODOCO addresses residual inflammation, a critical element in atherosclerotic cardiovascular disease (ASCVD). This drug, approved for use either alone or in conjunction with cholesterol-lowering medications, represents a significant breakthrough in cardiovascular care.

Who Are The Key Market Participants In The Atherosclerosis Drugs Market?

Major companies operating in the atherosclerosis drugs market are Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc.

Access The Complete Atherosclerosis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Which Geographic Region Represents The Largest Atherosclerosis Drugs Market Share?

North America was the largest region in the atherosclerosis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Atherosclerosis Drugs Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Browse Through More Reports Similar to the Global Atherosclerosis Drugs Market 2026, By The Business Research Company

Atherosclerosis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Atorvastatin Market Report 2026

https://www.thebusinessresearchcompany.com/report/atorvastatin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795